Tapentadol

Brand Names: Palexia, Nucynta

Drug Class: Opioid Analgesic with Norepinephrine Reuptake Inhibitor Activity

Overview

Tapentadol is a centrally-acting analgesic with dual mu-opioid receptor agonist and norepinephrine reuptake inhibitor activity, indicated for management of acute pain severe enough to require opioid therapy when alternative treatments are inadequate. It provides opioid-level analgesia while potentially offering improved gastrointestinal tolerability compared to traditional opioids.

Mechanism of Action

Tapentadol exerts its analgesic effects through two complementary mechanisms: (1) mu-opioid receptor agonism similar to traditional opioids, and (2) inhibition of norepinephrine reuptake, which enhances descending inhibitory pain pathways in the central nervous system.

Indications

  • Management of acute pain severe enough to require an opioid analgesic in adults
  • Use only when alternative non-opioid treatments are ineffective, not tolerated, or would be otherwise inadequate

Common Doses

  • 50 mg
  • 75 mg
  • 100 mg

Dosage

Individualized based on pain severity and patient response. Typically initiated at 50-100 mg every 4-6 hours as needed for pain, with maximum daily dose of 700 mg on first day and 600 mg on subsequent days. Dose adjustments required for hepatic impairment.

Contraindications

  • Significant respiratory depression
  • Acute or severe bronchial asthma in unmonitored setting or without resuscitative equipment
  • Known or suspected gastrointestinal obstruction, including paralytic ileus
  • Hypersensitivity to tapentadol or any product ingredients
  • Concurrent use of MAOIs or within 14 days of MAOI use

Side Effects

  • Nausea, vomiting, constipation, dizziness, somnolence
  • Pruritus, dry mouth, headache, fatigue
  • Serious adverse reactions: respiratory depression, addiction, withdrawal, seizures
  • Gastrointestinal adverse reactions including paralytic ileus
  • Opioid-induced hyperalgesia and allodynia

Interactions

  • Benzodiazepines and other CNS depressants: increased risk of respiratory depression and sedation
  • Serotonergic drugs (SSRIs, SNRIs, TCAs, triptans): risk of serotonin syndrome
  • MAOIs: contraindicated due to risk of serotonin syndrome or opioid toxicity
  • Mixed agonist/antagonist opioids: may reduce analgesic effect or precipitate withdrawal
  • Muscle relaxants: enhanced neuromuscular blockade and respiratory depression
  • Alcohol and other opioids: additive CNS depression effects

Counseling Points

  • Take only as prescribed; do not increase dose or frequency without medical advice
  • Avoid alcohol and other CNS depressants while taking this medication
  • Do not crush, chew, or break tablets - swallow whole
  • May cause dizziness or drowsiness - avoid driving or operating machinery until effects are known
  • Store securely to prevent misuse, abuse, or accidental ingestion by others
  • Dispose of unused medication properly
  • Seek immediate medical attention for signs of overdose: slow breathing, extreme sleepiness, inability to wake up